IFM Investors Pty Ltd Takes Position in United Therapeutics Corporation $UTHR

Posted by Brian Himes on Jul 4th, 2026

IFM Investors Pty Ltd bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm bought 8,878 shares of the biotechnology company’s stock, valued at approximately $5,264,000.

A number of other hedge funds have also recently added to or reduced their stakes in UTHR. Avoro Capital Advisors LLC grew its holdings in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC grew its holdings in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Janus Henderson Group PLC increased its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Finally, Darwin Global Management Ltd. purchased a new position in United Therapeutics during the third quarter worth approximately $317,617,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total value of $4,586,248.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,960,240.32. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 8,750 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $538.15, for a total value of $4,708,812.50. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,158,119.40. This represents a 31.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 632,718 shares of company stock valued at $356,533,651. Corporate insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on UTHR. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.42.

View Our Latest Stock Analysis on UTHR

United Therapeutics Stock Performance

United Therapeutics stock opened at $555.91 on Friday. The stock’s 50 day moving average price is $558.34 and its 200 day moving average price is $527.84. The firm has a market capitalization of $23.60 billion, a PE ratio of 20.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.58. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the business earned $6.63 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.